Human Investing LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Human Investing LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, Holdings Channel.com reports. The fund purchased 86 shares of the biopharmaceutical company’s stock, valued at approximately $61,000.

Several other hedge funds have also modified their holdings of REGN. International Assets Investment Management LLC lifted its holdings in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. KBC Group NV lifted its holdings in Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after buying an additional 102,198 shares during the period. Icon Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares during the period. Finally, State Street Corp lifted its holdings in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $673.60 on Monday. The firm has a 50-day moving average of $706.92 and a 200-day moving average of $896.16. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. The company has a market cap of $74.02 billion, a PE ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $11.86 EPS. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date is Thursday, February 20th.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Citigroup cut their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. TD Cowen cut their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Oppenheimer cut their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.